2211 (2211) Fair Value & Analysis

Healthcare · Market cap HK$50.3M

2 2211 2211 · HK

PriceHK$0.4450

Fair ValueHK$0.3700

Upside-16.9%

Quality45/100

Watch 2211 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$0.2400 – HK$0.4600

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price −14.4% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.4450 – HK$5.27 · fair‑value band HK$0.2400 – HK$0.4600 · the HK$0.4450 price screens above the HK$0.3700 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2211 (2211) currently trades at HK$0.4450, while our model-based Fair Value estimate is HK$0.3700 — implying the stock looks roughly 16.9% overvalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 2211 generated revenue of HK$537M at a net margin of -4.5%. Revenue declined 39.5% year over year. It earns a return on equity of -7.1%. Net debt stands at HK$11.6M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$537M

Revenue growth (YoY) -39.5%

Net margin -4.5%

Return on equity -7.1%

Free cash flow −HK$59.9M FY2025

Operating margin -1.3%

More key figures

Net debt HK$11.6M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2211 reported revenue of HK$712M in FY2025 versus HK$1.2B in FY2021, a compound −12.0%/yr. Reported net income was −HK$26.0M in FY2025.

Revenue −12.0%/yr

FY21 HK$1.2B

FY22 HK$1.3B

FY23 HK$1.3B

FY24 HK$1.1B

FY25 HK$712M

Net income

FY21 −HK$675M

FY22 −HK$188M

FY23 −HK$105M

FY24 HK$413K

FY25 −HK$26.0M

Is 2211 fairly valued? → Check now

Similar stocks

6 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
JD Health International Inc JDHIF	$5.85	$7.13	+22%
6618 6618	HK$34.16	HK$33.08	-3%
Alibaba Health Information Technology Limited ALBBY	$8.27	$6.61	-20%
0241 0241	HK$3.08	HK$2.04	-34%
Raia Drogasil S.A RADL3	R$17.46	R$16.13	-8%
Yifeng Pharmacy Chain Co 603939	¥20.91	¥22.00	+5%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2211 (2211) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.3700 versus a price of HK$0.4450 — about −17% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2211?

Our model-based fair value for 2211 is HK$0.3700 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.4450.

What is the quality score of 2211?

2211 has a Quality Score of 45/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2211 (2211)?

2211 reported trailing-twelve-month revenue of about HK$537M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2211?

The net profit margin of 2211 is about -4.5%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.